Hematology TimesBortezomib may overcome resistance in WMNovember 19, 2018Lymphoma & Plasma Cell DisordersNon-Hodgkin LymphomaAggressive Lymphomas
Hematology NewsFDA expands approval of brentuximab vedotin to PTCLNovember 16, 2018T Cell LymphomasLymphoma & Plasma Cell DisordersAggressive Lymphomas
Hematology TimesR-CHOP effective as first-line treatment in FLNovember 16, 2018Lymphoma & Plasma Cell DisordersNon-Hodgkin LymphomaAggressive LymphomasFollicular LymphomaB Cell Lymphoma
Hematology NewsNHL patients report fear, isolation during chemoNovember 15, 2018Aggressive LymphomasPatient & Survivor Care
Hematology NewsRelapsed MCL: Options for treatmentNovember 15, 2018Mantle Cell LymphomaAggressive LymphomasLymphoma & Plasma Cell DisordersB Cell Lymphoma
Hematology NewsFDA puts selinexor on fast track for DLBCLNovember 8, 2018Aggressive LymphomasLymphoma & Plasma Cell DisordersB Cell Lymphoma
Hematology TimesSelinexor on fast track for DLBCLNovember 8, 2018Lymphoma & Plasma Cell DisordersNon-Hodgkin LymphomaAggressive LymphomasB Cell Lymphoma
Hematology TimesCombo appears safe, active in rel/ref NHLNovember 6, 2018Lymphoma & Plasma Cell DisordersNon-Hodgkin LymphomaAggressive LymphomasFollicular LymphomaB Cell Lymphoma
Hematology TimesSandoz won’t seek U.S. approval for rituximab biosimilarNovember 6, 2018Lymphoma & Plasma Cell DisordersNon-Hodgkin LymphomaAggressive LymphomasFollicular LymphomaB Cell Lymphoma
Hematology NewsNovel risk factors for febrile neutropenia in NHL, solid tumorsNovember 2, 2018Patient & Survivor CareAggressive Lymphomas
Hematology TimesEC approves venetoclax in combo with rituximabNovember 2, 2018Leukemia, Myelodysplasia, TransplantationLymphoma & Plasma Cell DisordersPharmacyNon-Hodgkin LymphomaAggressive Lymphomas
Hematology TimesNovel risk factors for febrile neutropenia in NHL, other cancersNovember 1, 2018Lymphoma & Plasma Cell DisordersNon-Hodgkin LymphomaAggressive Lymphomas
Hematology NewsCheckpoint inhibitor plus rituximab is active in non-Hodgkin lymphomaOctober 31, 2018Aggressive LymphomasLymphoma & Plasma Cell DisordersFollicular LymphomaB Cell Lymphoma
Hematology NewsLine complications plague dose-adjusted EPOCH-R in non-Hodgkin lymphomaOctober 25, 2018Aggressive LymphomasThrombosisLymphoma & Plasma Cell DisordersB Cell Lymphoma
Hematology NewsFirst-line bortezomib prolongs survival in MCLOctober 25, 2018Mantle Cell LymphomaAggressive LymphomasLymphoma & Plasma Cell DisordersB Cell Lymphoma
